At Covance, they know that time is of the essence across their diabetes trials. Developing these trials in the most cost-efficient manner makes upfront planning crucial, but interrogating the best data resources to augment team expertise is a difficult task. Covance understands that delays to the development of a well-defined site list are costly, and that selection of the wrong investigators could cost a company crucial time to market. They use a variety of data sources to guide early site selection, honing in on the best possible sites and countries upfront to pre-identify the most effective sites for a trial. Their extensive data repositories allow them to create a master site list without the need for long, overly time-consuming feasibility questionnaires.
This webinar will discuss Covance’s well-refined internal process of site selection, and lessons learned that would benefit their industry partners in site selection.
Panelists will discuss:
- Using comprehensive protocol or concept analysis of internally available studies to identify similar trials
- How to incorporate sites from investigator performance databases driven by trial expertise
- Using data to hone in on specific patient locations
- Using all of this to develop strong site lists to save time and money in early study planning and site selection.
Kevin Melvin, Executive Director, Operational Strategy & Planning, Cardiovascular, Metabolic, Endocrine and Renal, Covance
Kevin Melvin has more than 28 years of experience in research in a range of therapeutic areas spanning the full development spectrum, from toxicology to regulatory approval. He leads the operational strategy planning group for the cardiovascular, metabolic, endocrine and renal therapeutic area which is responsible for designing clinical trials and developing strategies to provide their sponsors the highest probability of success.Message Presenter
Earl Seltzer, Sr. Director, Feasibility and Site Selection, Covance
Earl Seltzer has 15 years of industry experience working at both clinical research sites and CROs. He has 10 years’ experience in feasibility and 8 of which have been at CROs. He has special interests in data-driven approaches, innovative feasibility, pediatric trial feasibility, and the use of big data in feasibility.Message Presenter
J.B. Flinders, MPH, MBA; Sr. Director, Operational Strategy & Planning, Covance
J.B. Flinders has over 14 years of clinical and academic research experience. Flinders is experienced in designing and implementing operational, feasibility and analytic strategy across CVMER, rare disease, and oncology studies. Flinders incorporates cross-functional focus on strategic partnerships, risk mitigation, data intelligence and modeling.Message Presenter
Who Should Attend?
- Chief Medical Officer
- Chief Development Officer
- Medical Director
- Operational Director
- Clinical Development Director
- Clinical Development Manager
- Procurement Manager
What You Will Learn
- Protocols to refine inclusion/exclusion criteria
- Methods to utilize/analyze investigator performance
- Real-world data analysis and its role in site selection
- Methodology of site list development
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.
Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.
Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.